Ramoplanin: A lipoglycodepsipeptide antibiotic

Annals of Pharmacotherapy

Volumn 39, Issue 5, 2005, Pages 863-868

  Farver, Debra K ^a   Hedge, Dennis D ^a   Lee, Steven C ^a  

^a SOUTH DAKOTA STATE UNIVERSITY   (United States)

Author keywords

A 16686; A 16686A; MDL 62198; Ramoplanin

Indexed keywords

BETA LACTAM ANTIBIOTIC; DALFOPRISTIN PLUS QUINUPRISTIN; GLYCOPEPTIDE; LINEZOLID; METRONIDAZOLE; RAMOPLANIN; TEICOPLANIN; VANCOMYCIN;

ABDOMINAL PAIN; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL ACTIVITY; BACTEREMIA; BACTERIAL COLONIZATION; BACTERIAL INFECTION; BACTERICIDAL ACTIVITY; CLINICAL TRIAL; CLOSTRIDIUM DIFFICILE; CROSS RESISTANCE; DIARRHEA; DOSE RESPONSE; DRUG ABSORPTION; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG STRUCTURE; DYSPEPSIA; ENTEROCOCCUS; FLATULENCE; GRAM POSITIVE BACTERIUM; HUMAN; IN VITRO STUDY; NAUSEA; PRIORITY JOURNAL; REVIEW; VANCOMYCIN RESISTANT ENTEROCOCCUS;

ADULT; ANTI-BACTERIAL AGENTS; CLINICAL TRIALS; CLOSTRIDIUM DIFFICILE; DEPSIPEPTIDES; DIARRHEA; HUMANS; MICROBIAL SENSITIVITY TESTS;

EID: 17644384052     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1E397     Document Type: Review

References (45)

1. Jones RN. Resistance patterns among nosocomial pathogens. Chest 2001;119:397S-404S.
2. Joyce AM, Burns DL. Recurrent Clostridium difficile colitis. Postgrad Med 2002;112:53-65.
3. Cavalleri B, Pagani H, Volpe G, Selva E, Parenti F. A-16686, a new antibiotic from Actinoplanes. I. Fermentation, isolation and preliminary physico-chemical characteristics. J Antibiot (Tokyo) 1984;37:309-17.
4. Pallanza R, Berti M, Scotti R, Randisi E, Arioli V. A-16686, a new antibiotic from Actinoplanes. II. Biological properties. J Antibiot (Tokyo) 1984;37:318-24.
5. Journal articles and presentations regarding ramoplanin. Waltham, MA. www.oscient.com/products/scientific-publications.asp (accessed 2004 July 12).
6. Oscient Pharmaceuticals completes enrollment in Phase II trial of ramoplanin for Clostridium difficile-associated diarrhea. Waltham, MA. http://investors.oscient.com/phoenix.zhtml?c=97238&p=irol- newsArticle&ID=583157&highlight (accessed 2004 July 12).
7. Oscient Pharmaceuticals releases preliminary results from phase II ramoplanin trial for Clostridium difficile associated diarrhea. Waltham, MA. http://investors.oscient.com/phoenix.zhtml?c=irol-newsArticle&ID= 602853&highlight (accessed 2004 October 18).
8. McCafferty DG, Cudic P, Fankel BA, Barkallah S, Kruger RG, Li W. Chemistry and biology of the ramoplanin family of peptide antibiotics. Biopolymers 2002;66:261-84.
9. Boger DL. Vancomycin, teicoplanin and ramoplanin: synthetic and mechanistic studies. Med Res Rev 2001;21:356-81.
10. Jiang W, Wanner J, Lee RJ, Bounaud PY, Boger DJ. Total synthesis of the ramoplanin A2 and ramoplanose aglycon. J Am Chem Soc 2003;125:1877-87.
11. Hu Y, Helm J, Chen L, Ye X, Walker S. Ramoplanin inhibits bacterial transglycosylases as a dimer to lipid II. J Am Chem Soc 2003;125:8736-7.
12. Johnson CC, Taylor S, Pitsakis P, May P, Levison ME. Bactericidal activity of ramoplanin against antibiotic-resistant enterococci. Antimicrob Agents Chemother 1992;36:2342-5.
13. Lawrence T, Rotstein C, Beam TR Jr, Gorzynski EA, Amsterdam D. In vitro activities of ramoplanin, selected glycopeptides, fluoroquinolones, and other antibiotics against clinical bloodstream isolates of gram-positive cocci. Antimicrob Agents Chemother 1993;37:896-900.
14. Romeo B, Kaschube M, Cavenaghi L, Borgonovi M, Jaulhac B, Monteil H, et al. Repeated doses of ramoplanin orally administered to healthy male volunteers: tolerability, lack of absorption and effect on the stool microflora. In: Programs and Abstracts of the 33rd Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, DC 1993;33:200.
15. Rew Y, Shin D, Hwang I, Boger DL. Total synthesis and examination of three key analogues of ramoplanin: a lipoglycodepsipeptide with potent antibiotic activity. J Am Chem Soc 2004;126:1041-3.
16. Chen L, Yuan Y, Helm JS, Hu Y, Rew Y, Shin D, et al. Dissecting ramoplanin: mechanistic analysis of synthetic ramoplanin analogues as a guide to the design of improved antibiotics. J Am Chem Soc 2004;126:7462-3.
17. Citron DM, Merriam CV, Tyrrell KL, Warren YA, Fernandez H, Goldstein EJC. In vitro activities of ramoplanin, teicoplanin, vancomycin, linezolid, bacitracin, and four other antimicrobials against intestinal anaerobic bacteria. Antimicrob Agents Chemother 2003;47:2334-8.
18. Rolston KV, Dholakia N, Ho DH, LeBlanc B, Dvorak T, Streeter H. In-vitro activity of ramoplanin (a novel lipoglycopeptide), vancomycin, and teicoplanin against gram-positive clinical isolates in cancer patients. J Antimicrob Chemother 1996;38:265-9.
19. O'Hare MD, Ghosh G, Felmingham D, Gruneberg RN. In-vitro studies with ramoplanin (MDL 62,198): a novel lipoglycopeptide antimicrobial. J Antimicrob Chemother 1990;25:217-20.
20. Neu HC, Neu NM. In vitro activity of A-16686, a new glycopeptide. Chemotherapy 1986;32:453-7.
21. O'Hare MD, Felmingham D, Gruneberg RN. The in vitro activity of ramoplanin (A-16686/MDL 62,198), vancomycin and teicoplanin against methicillin-susceptible and methicillin-resistant Staphylococcus spp. Drugs Exp Clin Res 1988;14:617-9.
22. Manzor O, Pawlak J, Saravolatz L. In-vitro activity of 29 antimicrobial agents against penicillin-resistant and intermediate isolates of Streptococcus pneumoniae. J Antimicrob Chemother 1999;43:31-6.
23. Ling L, Puyang X, Moir DT, Sinclair A, Warner M, Woodford N, et al. In vitro activity of ramoplanin against multidrug-resistant staphylococci and enterococci (abstract 166). In: Programs and Abstracts of the 41st Annual Meeting of the Infectious Diseases Society of America, San Diego, October 9-12, 2003.
24. Blosser-Middleton RS, Leach T, Thornsbery C, Sahm D. In vitro activity of ramoplanin, a novel glycolipodepsipeptide, against Clostridium difficile (poster 171). In: Programs and Abstracts of the 41st Annual Meeting of the Infectious Diseases Society of America, San Diego, October 9-12, 2003.
25. Shonekan D, Mildvan D, Handwerger S. Comparative in vitro activities of teicoplanin, daptomycin, ramoplanin, vancomycin, and PD127,391 against blood isolates of gram-positive cocci. Antimicrob Agents Chemother 1992;36:1570-2.
26. Collins LA, Eliopoulos GM, Wennersten CB, Ferraro MJ, Moellering RC Jr. In vitro activity of ramoplanin against vancomycin-resistant gram-positive organisms. Antimicrob Agents Chemother 1993;37:1364-6.
27. Wise R, Andrews JM, Boswell FJ, Ashby JP. The in-vitro activity of linezolid (U-100766) and tentative breakpoints. J Antimicrob Chemother 1998;42:721-8.
28. Bain KT, Wittbrodt ET. Linezolid for the treatment of resistant gram-positive cocci. Ann Pharmacother 2001;35:566-75. DOI 10.1345/aph.10276
29. Dowzidky M, Nadler HL, Feger C, Talbot G, Bompart F, Pease M. Evaluation of in vitro activity of quinupristin/dalfopristin and comparator antimicrobial agents against worldwide clinical trial and other laboratory isolates. Am J Med 1998;105:34S-42S.
30. Auskenthaler R, Courvalin P, Feger C, Roche G. In vitro activity of quinupristin/dalfopristin in comparison with five antibiotics against worldwide clinical isolates of staphylococci. Clin Microbiol Infect 2000;6:608-12.
31. Doern GV, Heilmann KP, Huynh HK, Rhomberg PR, Coffman SL, Brueggemann AB. Antimicrobial resistance among clinical isolates of Streptococcus pneumoniae in the United States during 1999-2000, including a comparison of resistance rates since 1994-1995. Antimicrob Agents Chemother 2001;45:1721-9.
32. Pelaez T, Alcala L, Alonso R, Martin-Lopez A, Garcia-Arias V. In vitro activity of ramoplanin against Clostridium difficile, including strains with reduced susceptibility to vancomycin or with resistance to metronidazole (poster E-2188). In: Programs and Abstracts of the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, September 14-17, 2003.
33. Poutanen S, Simor AE. Clostridium difficile-associated diarrhea in adults. CMAJ 2004;171:51-8.
34. Johnson S, Gerding DN. Clostridium difficile-associated diarrhea. Clin Infect Dis 1998;26:1027-36.
35. Johnson S, Clabots CR, Linn FV, Olson MM, Peterson LR, Gerding DN. Nosocomial Clostridium difficile colonization and disease. Lancet 1990;336:97-100.
36. Miller MA, Hyland M, Ofner-Agostini M, Gourdeau M, Ishak M. Morbidity, mortality, and healthcare burden of nosocomial Clostridium difficile-associated diarrhea in Canadian hospitals. Infect Control Hosp Epidemiol 2002;23:137-40.
37. Gerding DN, Johnson S, Peterson LR, Mulligan ME, Silva J Jr. Clostridium difficile-associated diarrhea and colitis. Infect Control Hosp Epidemiol 1995;16:459-77.
38. Fekety R. Guidelines for the diagnosis and management of Clostridium difficile-associated diarrhea and colitis. Am J Gastroenterol 1997;92:739-50.
39. Tailor SAN, Bailey EM, Rybak MJ. Enterococcus, an emerging pathogen. Ann Pharmacother 1993;27:1231-42.
40. Mayhall CG. The epidemiology and control of VRE: still struggling to come of age. Infect Control Hosp Epidemiol 1999;20:650-2.
41. Staphylococcus aureus resistant to vancomycin - United States, 2002. MMWR Morb Mortal Wkly Rep 2002;51:565-7.
42. Wong MT, Kauffman CA, Standiford HC, Linden R, Fort G, Fuchs HJ, et al. Effective suppression of vancomycin-resistant Enterococcus species in asymptomatic gastrointestinal carriers by a novel glycolipodepsipeptide, ramoplanin. Clin Infect Dis 2001;33:1476-82.
43. Patel R. Clinical impact of vancomycin-resistant enterococci. J Antimicrob Chemother 2003;51(suppl 3):iii,13-21.
44. Montecalvo MA. Ramoplanin: a novel antimicrobial agent with the potential to prevent vancomycin-resistant enterococcal infection in high-risk patients. J Antimicrob Chemother 2003;51(suppl 3):31-5.
45. Stiefel U, Pultz NJ, Helfand MS, Donskey CJ. Efficacy of oral ramoplanin for inhibition of intestinal colonization by vancomycin-resistant enterococci in mice. Antimicrob Agents Chemother 2004;48:2144-8.